| Literature DB >> 34773966 |
Francesca Jean1,2, Susan Stasiuk1,2, Tatiana Maroilley1,2, Catherine Diao1,2, Andrew Galbraith1,2, Maja Tarailo-Graovac3,4.
Abstract
BACKGROUND: Intragenic modifiers (in-phase, second-site variants) are known to have dramatic effects on clinical outcomes, affecting disease attributes such as severity or age of onset. However, despite their clinical importance, the focus of many genetic screens in model systems is on the discovery of extragenic variants, with many labs still relying upon more traditional methods to identify modifiers. However, traditional methods such as PCR and Sanger sequencing can be time-intensive and do not permit a thorough understanding of the intragenic modifier effects in the context of non-isogenic genomic backgrounds.Entities:
Keywords: C. elegans; CRISPR/Cas9; Intragenic modifier; Mutagenesis screen; Whole genome sequencing
Mesh:
Substances:
Year: 2021 PMID: 34773966 PMCID: PMC8590768 DOI: 10.1186/s12864-021-08142-8
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Hatching rates for each of the strains containing intragenic variants
| Strain | Average Eggs Laid | Hatching Rate | N |
|---|---|---|---|
| 188.68 | 89.48% | 41 | |
| 262.4 | 97.29% | 5 | |
| 167.8 | 2.31% | 49 | |
| 109 | 66.17% | 15 | |
| 250.6 | 9.89% | 10 | |
| 199.89 | 67.42% | 9 | |
| 216.1 | 68.97% | 16 | |
| 55.11 | 95.35% | 9 | |
| 137.23 | 42.17% | 13 | |
| 148.65 | 20.49% | 17 | |
| 250.33 | 11.21% | 12 | |
| 130.11 | 90.98% | 9 | |
| 47 | 98.76% | 9 | |
| 111.5 | 87.05% | 10 | |
| 99 | 82.57% | 10 | |
| 106.8 | 51.34% | 10 | |
| 118.5 | 41.43% | 10 | |
| 152.2 | 64.74% | 10 |
Fig. 3Summary of suppression strength of each of the strains containing intragenic secondary variants. A-C. Summary of population assay. Between 7 and 33 plates were tested for each genotype. A. Kaplan-Meier graph showing the percentage of plates of each genotype to reach a population size of 50. B. Kaplan-Meier graph illustrating the percentage of plates of each genotype to reach an L4 or adult population size of 50. C. Kaplan-Meier graph showing the percentage of plates of each genotype that ultimately resulted in population death. Plates that had not reached either of the population size metrics or had died out by 30 days were considered terminated. Both the hatching and population assays were performed at 24.7 °C unless otherwise specified
Fig. 1Overview of the mutagenesis screen. In brief, synchronized L4 zyg-1(it25) worms were exposed to EMS, ENU, or a cocktail of the two mutagens. Following incubation at the permissive temperature, F2 embryos were harvested and transferred to the restrictive temperature for 5–6 weeks to select for suppressing mutants. Homozygous populations that were validated to be suppressors had their gDNA extracted and were submitted for whole-genome sequencing (WGS). WGS files were analyzed using an in-house bioinformatics pipeline to produce a short-list of variants and these variants were manually curated to identify intragenic suppressing candidates. Finally, candidate intragenic variants were validated using CRISPR and phenotypic assays
Fig. 2Comparison between Sanger and whole genome sequencing. A. Cost and time investment in using Sanger sequencing to identify strains containing intragenic suppressing variants. B. Cost and time investment in using whole genome sequencing to identify strains containing intragenic suppressing variants. C. Pros, cons, and rate limiting steps for Sanger and whole genome sequencing
Overview of strains containing intragenic variants
| Strain | Mutagenesis | Filtered Variants | Position(s) | Ref/Alt | Variant Effects |
|---|---|---|---|---|---|
| N/A | N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | N/A | N/A | |
| EMS | 122 | 5,651,146 | C/T | c.1154C > T; p.A385V | |
| ENU | 65 | 5,650,939 5,650,947 | C/A T/G | c.947C > A; p.P316H c.955 T > G; p.S319A | |
| EMS/ENU | 188 | 5,651,254 | G/A | c.1262G > A; p.G421E | |
| EMS/ENU | 176 | 5,651,146 | C/T | c.1154C > T; p.A385V | |
| EMS/ENU | 174 | 5,649,756 | G/A | c.-18G > A | |
| ENU | 73 | 5,651,219 5,651,252 | T/A T/C | c.1227 T > C; p.H409= c.1260 T > A; p.N420K | |
| ENU | 84 | 5,653,611 | A/G | c.1597A > G; p.K533E | |
| ENU | 78 | 5,650,847 | A/C | c.938A > C; p.D313A | |
| ENU | 70 | 5,651,254 | G/A | c.1262G > A; p.G421E | |
| EMS/ENU | 70 | 5,653,339 | T/C | Revertant | |
| EMS/ENU | 47 | 5,649,770 | T/A | c.-4 T/A | |
| EMS/ENU | 126 | 5,651,146 | C/T | c.1154C > T; p.A385V | |
| EMS/ENU | 123 | 5,651,073 | G/A | c.1081G > A; p.E361K | |
| EMS/ENU | 116 | 5,650,948 | C/T | c.956C > T; p.S319F | |
| EMS/ENU | 111 | 5,650,846 | G/A | c. 937G > A; p.D313N |
Fig. 4Summary of the positions of the intragenic variants within zyg-1/ZYG-1 and their relative hatching rates. The upper image shows the zyg-1 gene arrangement along with the two 5′ UTR suppressing variants and the original it25 variant. Below, the structure of the ZYG-1 protein is outlined, with the kinase and polo domains indicated in thick blue boxes and intragenic variants affecting the protein coding region listed underneath. Variants are colour-coded in green based on their hatching ability (confirmed through testing either the mutagenized strain or the CRISPR strain). Variants that occurred twice are indicated with a plus sign, variants that occurred thrice are indicated with an asterisk, and variants that co-occurred are indicated with either a dollar sign or hashtag
Fig. 5Predicted position of the intragenic variants within ZYG-1. Suppressing intragenic variants are coloured in yellow whereas the primary phenotype-causing zyg-1(it25) mutation is in red. Figure created with PyMOL with the predicted ZYG-1 structure downloaded from AlphaFold (ID: AF-Q9GT24-F1) [12, 13]
Summary of CRISPR-generated strains verifying a subset of candidate intragenic and extragenic suppressing variants
| Gene | Originating Strain | Injected Strain | Variant Effects | Hatching Rate (N) | Suppressor? | Phenotype | Strain Name |
|---|---|---|---|---|---|---|---|
| p.A385V | 48.02% (5) | Yes | Viability | ||||
| p.A385V | 94.78% (5) | N/A | Viability | ||||
| p.A385V | 93.13% (5) | N/A | Viability | ||||
| p.N420K and p.H409= | 37.18% (8) | Yes | Viability | ||||
| p.K533E | 0.19% (8) | No | Embryonic Lethality | ||||
| p.K533E | 4.09% (5) | Yes | Viability | ||||
| p.D31V | 0% (4) | No | Embryonic Lethality | ||||
| p.G180R | 0% (5) | No | Embryonic Lethality | ||||
| p.P216S | 1.09% (5) | No | Embryonic Lethality | ||||
| c.-4 T/A | 82.09% (7) | Yes | Viability | ||||
| c.-4 T/A | 19.48% (7) | Yes | Viability |
Guide RNAs designed for zyg-1 intragenic suppressors
| Strain | gRNA | PAM |
|---|---|---|
| MTG309 | GGTTTGAAGTTGCAGCTCAA | GGG |
| MTG320 | AGTTGATGAAATGGTTCAAA | CGG |
| MTG329 | CGAGCAATGTCTTAACGGAA | TGG |
| MTG398 | TTGATCAACTATGAGATGAG | CGG |
Donor constructs (ssODNS) designed for re-creating intragenic suppressors using homology-directed repair
| Strain | ssODN Sequence (5′➔3′) |
|---|---|
| MTG309 | TATATTGTTGAATTGGATACTCGTTGTCGGTTTGAGGTAGTAGCTCAAGGGAATTTCGTTAAACGAATTTTGATTG |
| MTG320 | GGATTGTTCGTCAACGTAATCAATTCTTCTTCTCCTTTTCTTCCGCGTACTGTTCTATCAGGTATTCGGTGTACATAAACTGTTTGAACCATTTCATCAACTTCGACAATCAAAAT |
| MTG329 | CTGGAATAACACTTACAAAAGTGAATGAAGTATATGAATATCTAATAAGATTTGAACAATGTCTTAACGGAATGGATCGAGGAATGGTGTG |
| MTG398 | ATCTTATTTTTAGCGCACCAAGTGTTGATCAACTAAGAGATGAGCGGTGGGAAGAGTGGTTCAAGATTGAG |
Genotyping strategy to confirm insertion of the donor constructs
| Strain | Forward (5′➔3′) | Reverse (5′➔3′) | Length | Annealing T | RE |
|---|---|---|---|---|---|
| MTG309 | ACGACAGAGATCGAGGGAA | ACCGGAGGAGGATGTGAA | 777 bp | 61 °C | BbvI |
| MTG320 | ACGACAGAGATCGAGGGAA | ACCGGAGGAGGATGTGAA | 777 bp | 61 °C | Hpy166II |
| MTG329 | AGATGGTTGCTGTGACGATAAG | GGTACTCGATCAGTTCGCATAAA | 792 bp | 61 °C | BsrDI |
| MTG398 | CCACTCTTTGTCCCACTCTAAA | CTCTTAATCGCCACCTTCTCTC | 575 bp | 52.5 °C | DdeI |